ClinicalTrials.gg
RecruitingNCT06568640SAAE-RHUpdated Aug 23, 2024

Superselective Adrenal Arterial Embolization for Refractory Hypertension: A Proof-of-Concept Study

An interventional study of Superselective adrenal arterial embolization in Essential Hypertension, sponsored by Second Affiliated Hospital of Nanchang University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-23.

Sponsored by Second Affiliated Hospital of Nanchang University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Essential Hypertension with a site in China — 19 open to participants now, 20 under way, 2 of them phase 3. Essential Hypertension · China.

Planned enrollment
64th of 67
20 · median 297
Started
2024
with 7 others
No phase
22 of 76
8 open now
Primary completion
2027-12
later than 16 of 19 live
Registered
61st of 76
by date

Among the 76 studies in Essential Hypertension with a site in China, this one is the 64th largest by planned enrollment of the 67 interventional ones that give a count, is one of 8 that started in 2024, is one of 22 with no phase, reaches primary completion later than 16 of the 19 other live ones, and was the 61st registered.

Essential Hypertension

481 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

19 of the 76 studies in Essential Hypertension with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 Essential Hypertension studies recruiting now, 15 (35%) set no upper age limit and 20 (47%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Essential Hypertension with a site in China, or all of them as a file.
02

Study summary

The subjects of this study were patients with essential refractory hypertension. The purpose of this study is to evaluate the safety and efficacy of superselective adrenal arterial embolization (SAAE) in patients with primary refractory hypertension and to explore the possibility of SAAE in patients with primary refractory hypertension.After the subject completes the SAAE, an 8-week follow-up will be conducted to assess the safety and effectiveness of the SAAE.

Read the detailed description

The subjects of this study were patients with essential refractory hypertension. The study design was a single-center, open-label, self-controlled, single-arm, prospective study. The purpose of this study is to evaluate the safety and efficacy of superselective adrenal arterial embolization (SAAE) in patients with primary refractory hypertension and to explore the possibility of SAAE in patients with primary refractory hypertension.After the subject completes the SAAE, an 8-week follow-up will be conducted to assess the safety and effectiveness of the SAAE.

03

Conditions studied

  • Essential Hypertension

Keywords

  • Essential hypertension
  • Superselective adrenal arterial embolization
  • Interventional therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years, no gender restrictions;
  • Primary hypertension: Taking three antihypertensive drugs, including a - diuretic, with an average office systolic blood pressure ≥150 mmHg measured three times;
  • Duration of hypertension greater than 6 months;
  • Standing plasma aldosterone and renin activity not below the lower limit of the unit's reference range;
  • Signed form.

Exclusion criteria

Exclusion Criteria:

  • Morning cortisol level \< 4.3 µg/dL; estimated (eGFR) \< 45 mL/min/1.73 m²; serum potassium level > 5.5 mmol/L;
  • Type 1 diabetes, uncontrolled hyperthyroidism, malignant arrhythmias, malignant tumors, decompensated heart failure, severe liver dysfunction, severe hematological diseases, severe obstructive sleep apnea syndrome, history of myocardial infarction, syncope, cerebral hemorrhage, or cerebral infarction within the past 3 months;
  • Pregnant women or those planning to conceive within the next year;
  • Presence of other severe organic diseases that would make the patient unable to tolerate superselective adrenal arterial embolization;
  • Adrenal mass with a diameter exceeding 2 cm;
  • Severe allergy to contrast agents;
  • Patients enrolled or planning to participate in other clinical studies that could impact the results of this study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Interventional treatment group

    superselective adrenal arterial embolization

    Procedure: Superselective adrenal arterial embolization

Interventions

  • ProcedureSuperselective adrenal arterial embolization

    Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.

    Also known as: Adrenal artery ablation, catheter-based adrenal ablation, Transcatheter Arterial Ablation, Transarterial embolization, percutaneous adrenal arterial embolization, selective adrenal artery embolization

06

What researchers measure

Primary outcomes

  1. 24-hour mean systolic blood pressure

    ambulatory blood pressure monitoring

    Time frame: 8 weeks after SAAE

Secondary outcomes

  1. Proportion of patients with non-refractory hypertension

    Describe how many patients are converted from refractory hypertension to non-refractory hypertension

    Time frame: 8 weeks after SAAE

  2. 24-hour mean diastolic blood pressure

    ambulatory blood pressure monitoring

    Time frame: 8 weeks after SAAE

  3. Safety monitoring:Procedure-related complications

    Procedure-related complications include but are not limited to the following: transient arrhythmia during the SAAE procedure, incidence of hypertensive encephalopathy; post-procedure complications such as pleural effusion, brachial artery pseudoaneurysm, brachial artery thrombosis, pancreatitis, and contrast-induced nephropathy.

    Time frame: up to 8 weeks

  4. Safety monitoring:Adrenal-related hormones

    Plasma aldosterone concentration, plasma renin activity, plasma cortisol concentration, corticotropin-releasing hormone level, blood catecholamine levels, sex hormone levels.

    Time frame: 8 weeks after SAAE

  5. Safety monitoring:Kidney function

    Estimated Glomerular Filtration Rate

    Time frame: 8 weeks after SAAE

  6. Safety monitoring:Plasma electrolyte levels

    Plasma potassium

    Time frame: 8 weeks after SAAE

Other outcomes

  1. Daytime average systolic blood pressure

    Daytime average systolic blood pressure

    Time frame: 8 weeks after SAAE

  2. Daytime average diastolic blood pressure

    Daytime average diastolic blood pressure

    Time frame: 8 weeks after SAAE

  3. Nighttime average systolic blood pressure

    Nighttime average systolic blood pressure

    Time frame: 8 weeks after SAAE

  4. Nighttime average diastolic blood pressure

    Nighttime average diastolic blood pressure

    Time frame: 8 weeks after SAAE

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2027, 40 months after the start.

Of 70 non-industry interventional studies with no phase under Essential Hypertension, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 47. This study's planned 40 months is above that.

Counting every sponsor, half of 80 studies reached it within 20 months; a quarter within 8 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2024
First posted
Aug 23, 2024
StartActual
Aug 1, 2024
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Aug 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06568640
Lead sponsor
Second Affiliated Hospital of Nanchang University
Responsible party
Yifei Dong (Deputy Director of the Department of Cardiology, Second Affiliated Hospital of Nanchang University) — Principal investigator
First posted
Aug 23, 2024
Start date
Aug 1, 2024
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 23, 2024

Study contacts

Yifei the second affiliated hospital of Nanchang university, Doctor
Contact
yf_dong66@126.com
(0791)86209562
Yifei Dong, Doctor
principal investigator · Second Affiliated Hospital of Nanchang University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion